Viking Therapeutics enters the week after a violent 36% price spike, leaving nearly 20% of its float short and options traders more skittish than at any point in months.
The move is impossible to ignore. VKTX closed at $40.85 on Tuesday, up 35.7% on the day and 36.4% on the week — a magnitude that concentrates the mind when 19.8% of the free float remains short. That is a heavy position by any standard: roughly one in five available shares is betting against the stock. The ORTEX short score had been running near 74-75 all month before dipping to 72.6 on Tuesday, which still ranks in the 7th percentile for short-score risk across the broader universe — a red-flag reading. With a days-to-cover of 12.4 per the most recent FINRA print, any short forced to exit faces a meaningful queue.
The borrowing market tells a more nuanced story, however. Availability has tightened over the week — dropping from around 210% to 179% — but remains within the normal range. Cost to borrow has jumped 136% over the same period, rising from 0.27% to 0.65%, yet in absolute terms that is still a cheap borrow. Shorts have not been flushed out of the lending pool; they have stayed put. Short interest itself is almost unchanged on the week, down just 0.05%. That combination — stock up 36%, shorts holding their ground, borrow still accessible — frames this week's tension precisely: the bears have not covered, and the stock has run straight through them.
Options positioning has grown more defensive into the rally, which is notable. The put/call ratio hit 0.23 on Tuesday, more than two standard deviations above its 20-day mean of 0.20 — the most elevated defensive reading in several months. That is counterintuitive on a day the stock explodes higher; it suggests a cohort of holders is now buying puts to protect fresh gains rather than piling further into calls. The 52-week PCR low is 0.16, so the reading is not extreme in absolute terms, but the z-score of 2.16 marks a genuine shift in hedging behaviour relative to recent norms.
The Street remains constructive but has not yet caught up with the stock. Truist Securities raised its target to $87 from $83 this morning, maintaining a Buy — one of the few same-day reactions to the move. The consensus mean target sits at $94.81, implying the stock still trades at a meaningful discount to Street fair value even after the spike. That said, JP Morgan had trimmed its target to $65 back in August, and Canaccord's $114 target from July now looks optimistic by different logic — the stock has moved toward targets that once seemed distant. Bulls point to the VK2735 auto-injector transition and the Ligand license agreement as structural supports; bears cite competition timelines and cash runway as the stock phases toward Phase 3 spending. The price-to-book multiple has expanded by roughly 1.2 points over the past 30 days, now at 7.6x, while the EV/EBITDA remains deeply negative, as expected for a pre-revenue biotech.
Insider activity adds a layer of context worth noting. The CEO Brian Lian sold 148,517 shares at $33.32 on July 29 — a $4.9 million open-market disposal — alongside the CFO and COO selling on the same day, none under a 10b5-1 plan. The net insider position over the past 90 days is negative $6.3 million. These were discretionary sales at prices well below this week's close, which limits their signalling weight today, but the cluster of C-suite selling at $33 — now 19% below Tuesday's close — is worth holding in mind as the stock pushes higher. The Chief Commercial Officer did buy 4,475 shares in March at $33.50, a modest counterpoint.
Q3 earnings are pencilled in for October 21. The two most recent quarterly prints produced negative stock reactions: down 2.2% the next day in July, and down 6.7% in April. Neither fall persisted meaningfully into the five-day window, but the pattern of post-earnings weakness is there. With short interest still near 20% of float and cost to borrow creeping higher, the dynamic to watch into October is whether the bears who stayed through this week's spike begin covering ahead of the print — or press their position further if the rally fades.
See the live data behind this article on ORTEX.
Open VKTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
